

A Canadian Isotope Success Story

Grant Malkoske, Vice President
Quality, Regulatory Affairs and Operations Services
MDS Nordion

Annual Meeting of the
Canadian Nuclear Association
June 11, 1997

Good morning ladies and gentlemen. I have enjoyed my conversations with many of you and I thank you for the opportunity to talk with you today.

Many of you in this room today have a focus on the development, marketing and operation or regulation of Candu reactors both here and around the world. Your job is to ensure that these facilities operate safely and provide clean, affordable electricity for thousands of homes and businesses. You do your job extremely well, and I want to commend each of you for your efforts. So, why am I here and why is MDS Nordion part of this distinguished group? As most of you know, we use nuclear science and technology to advance human life and health through a wide range of applications. We could not do this without the strong partnerships we have formed with the Canadian nuclear power industry.

MDS Nordion has a story to tell. It is not only our success story, it is your success story. More than that, it is Canada's success story.

As an industry, we are often challenged by activists, who fear and attack anything nuclear and who do not care to understand how vital nuclear energy and nuclear science are to an environmentally sound, economically healthy future. MDS Nordion has not escaped this kind of public scrutiny, but much of this criticism is muted by the tremendous contributions we have made to medicine and health care generally.

That is why it is so important for you to see MDS Nordion's story, not as an adjunct that belongs somewhere off to the side, but as a success story that everyone in this room is a part of.

In 1946, Roy Errington and his two employees began selling radium that had been stockpiled during World War II. This was to be the genesis of the company that today is MDS Nordion. Errington looked for ways to utilize radioisotopes in the health care field. An early application included the use of radium as a cancer treatment. In 1947, the NRX reactor came on line, and in 1952, Errington's small company became part of Atomic Energy of Canada Limited (AECL). This allowed him the access to state-of-the art research and development facilities and scientific resources. Roy Errington forged a partnership 50 years ago that endures today --the Canadian nuclear power program and MDS Nordion working together to make Canada the world leader in developing and applying life-saving technology.

Of course, Roy's company has been through many changes over the last 50 years. First, we were the AECL Commercial Products Division, then the AECL Radiochemical

Company and in 1988 we became Nordion International, which was successfully privatized in 1991. And since the last time this distinguished group assembled we changed again, and are now MDS Nordion. Our name change reflects our strong participation and integration into a dynamic health and life sciences company with a base in Canada and a global vision. And as we have just celebrated our 50th anniversary as a company, we will carry our proud heritage forward as we move ahead to meet the challenges of the next century.

I would like to recount some of this proud heritage for you. It is, after all, your heritage. I will be brief because many of you have not only heard some of this before, some of you were there. Nonetheless, I believe it is helpful to remember how we arrived here today as we focus on and define our industry's role in the new millennium.

In the 1950s, the use of radioisotopes in cancer therapy became widespread. Cobalt 60 was used to treat most of the diagnosed cancers of that time. In fact, Theratronics International continues to provide this equipment even today. It is safe to say that cobalt beam therapy has saved millions of lives around the world.

In 1958, the NRU reactor came on line. For 40 years it has been and remains the world's most important isotope production facility producing Cobalt 60 for cancer teletherapy and Molybdenum 99 for nuclear diagnostic imaging. It truly enabled Canada to take and hold a lead that no one in the world can challenge.

The very next year in 1959, the Rectilinear Scanner opened up a whole new realm of possibility and created a high demand for iodine 131 as this new tool for medical imaging became the state-of-the-art.

As we entered the decade of the 1960s, the use of cobalt 60 to sterilize medical disposable products emerged as a core element of our business. The sources of cobalt began with NRX and NRU, but with the production of cobalt at Douglas Point, Pickering, Embalse, Bruce, and Gentilly, Candu reactors have and continue to supply this vital raw material.

Today, 50% of the world's medical products are gamma sterilized. 80% of these products are sterilized with cobalt provided by MDS Nordion and Canada. In fact, over the past 27 years, MDS Nordion has shipped over 400 million curies of cobalt 60 around the world for health care applications.

The development that had perhaps the most impact on nuclear medicine was the marketing of fission product molybdenum 99 in 1972. This development quickly

transformed the way technetium 99m was supplied and forever transformed the diagnostic imaging process. To give you an idea about just how important MDS Nordion supplied molybdenum has become, 80% of the world supply comes from Canada. The technetium it generates accounts for 80% of the diagnostic procedures used by the nuclear medicine community. This equates to 50,000 procedures every day at hospitals around the world. Without this imaging technology the only other course of action is invasive surgery.

So you can see how the growing demand for technetium and the Canadian nuclear program's ability to supply it truly established our leadership as a supplier to the nuclear medicine community.

We did this by focusing on the needs of our customers and developing an unparalleled worldwide distribution system. And the market for molybdenum 99 continues to grow as we find new applications in the diagnosis of heart, kidney, bone and blood diseases.

We are assured of our lead in nuclear medicine imaging technology and the supply of molybdenum 99 by one of the most exciting developments in our long history. We are proud to be the new owners of not one, but two specialty reactors that will come on line in 1999 and 2000. Maple I and Maple II will be the first reactors in the world that are dedicated solely to isotope production.

These reactors, and the accompanying state-of-the-art processing facility, assure that a secure, stable supply of molybdenum 99 will be available when NRU is decommissioned and well into the next century. They are also symbolic of Canada's enduring commitment to leadership in this field. We are pleased to continue our partnership with AECL on this project. They will apply their world renowned expertise in reactor technology to design, build and operate these reactors at Chalk River on behalf of MDS Nordion.

There are many opportunities that we can capitalize on together as an industry. These are not just success stories we can share and feel good about, they are hard opportunities for business growth. One such opportunity is the growing marketplace for medical sterilization.

While the North American and European markets account for most of the medical sterilization done today, a major opportunity is stirring in the developing world. It is no exaggeration to say that these emerging markets have the potential to double the size of the medical sterilization market within the next 15 years.

I want to illustrate how these markets have the potential for expansion by looking at some interesting statistics. Gamma sterilization has reached a processing level of 173 million cubic feet worldwide, with 135 million cubic feet of the total (about 78%) accounted for by Europe and North America and 38 million cubic feet for the rest of the world.

The possibility of major growth in emerging markets becomes apparent when one considers the potential in two of the world's largest countries, India and China. According to the Health Industry Manufacturers Association, the Chinese market for medical technology products is growing at a rate of 23% and the Indian market is exceeding that slightly at a growth rate of 24%.

In each country, both local and multinational companies are rushing to expand capacity to service this growing demand and our industry is going to be a part of it. I know that on the energy side, AECL has also recognized the growing demand in the developing world, as Candu technology becomes the choice for nuclear power generation in China and other countries.

If we calculate the installed base of Cobalt used for medical sterilization and irradiation on a per capita basis we can get an interesting picture of this potential. The installed base of Cobalt in the US, for example, is estimated at 100 million curies and this equates to roughly 0.4 curies per capita. In China the installed base is 11 million curies with a per capita level that is only 2% of the US total and in India it is 2 million curies with a per capita level at 0.5% of the US amount, or only 0.002 curies per capita. When we consider that over 35% of the world's population lives in China and India alone, it becomes apparent that these markets present an immense opportunity.

Another exciting opportunity as we look to the future is food irradiation. Currently, single-use medical sterilization accounts for 80 % percent of the installed base of cobalt 60, with approximately 20 % utilized to treat other products including cosmetics, pharmaceuticals, packaging, food and spices. We have a huge and exciting opportunity to grow the food irradiation market exponentially.

Unfortunately, it is an opportunity borne of tragedy. In 1993, Nancy Donley of Washington State took her 6-year-old son, Alex, out for a hamburger. Within a few weeks he and four other children had died from E-coli poisoning, in an outbreak that made over 600 people ill.

The deaths that resulted from E-coli contamination at Jack-in-the-Box restaurants horrified the world and called attention to a food safety problem that results in 9,000 deaths every year. The debate over food safety continues today. Less than a month ago, *USA Today* ran an article describing a new \$43 million US food safety initiative unveiled by President Clinton to combat the increasing threat of food poisoning. These funds will be spent on an early warning monitoring system, public education and the development of new food safety technologies. The article briefly mentioned irradiation as one solution to preventing food poisoning in everything from apple juice to red meat.

At a recent International Meeting on Radiation Processing, I was encouraged by the efforts that some are making in the irradiation of food products in the United States, Belgium, France and South Africa.

However, I am sorry to say, we as an industry have not yet convinced society that we can be an important part of the solution. Nowhere more so than in Canada. For example, the United States Food and Drug Administration approved spices, produce and poultry for irradiation in the United States over five years ago. Just recently, MDS Nordion's petition for the irradiation of animal feed was approved by the US FDA. A petition has also been submitted to the FDA by one of our customers for the irradiation of red meat and is currently under review.

The world has at its disposal a life-saving technology to greatly reduce the risk of such tragedy happening again. This technology is food irradiation. And Canada is the world leader in supplying the cobalt 60, the equipment, and the expertise that makes food irradiation a commercially viable process. Yet in Canada, our regulatory approvals are far behind, with only spices, onions and potatoes approved for this process.

Other developments in the regulatory arena also point to expanded opportunities for our technology. By the year 2001, the produce industry will no longer be able to rely on methyl bromide, the primary treatment for fumigating fresh fruits and vegetables, due to its ozone depleting properties. The only replacement technology that has the potential to both effectively disinfest and preserve fresh produce is irradiation.

As an industry, we have failed so far to make commercially significant inroads with the largest processors of all these food products. We are told, "we do not want to become the targets of activist and besides, there is no demand for your technology and your products."

Further, supportive organizations all say, "It is your process. You get something going and we will join you. We are not going to push your technology and your process unless you take the lead."

There are a number of activist groups out there continuing their attempts to stop us, using scare tactics and pseudo-science. The most persistent of these is Food and Water, Inc. Why should a small group of opponents be taken seriously when we have such overwhelming support from scientists, academics and respected organizations? Because they are vocal and well-organized and we are not.

So, as you can tell, this is not just a history lesson today. Yes, MDS Nordion's story is a Canadian nuclear success story that we should all be telling and that we all can be taking credit for. But there is more to it than that. We are on the verge of a new century and many exciting breakthroughs, but we are still, all of us together, misunderstood by many Canadians and many around the world. They may not be environmental activists, but they are, at best, uneasy about the nuclear industry. For example, earlier I mentioned Nancy Donley who lost her son to food poisoning. Nancy went on to found S-T-O-P, Safe Tables Our Priority. Nancy and her food safety advocacy group oppose food irradiation, even though it could have prevented her son's death.

How do you personally feel about the benefits of nuclear medicine and food irradiation? What do your family, friends and spouse think about it? Do you talk about the benefits of these vital technologies at social events or family discussions?

So first, we can work with renewed vigor to educate people about the contributions we have made together as an industry to provide clean, environmentally safe energy; to protect and enhance human life; and to lead the world in the development and application of nuclear science and technology. MDS Nordion's story can be a vital part of this effort.

Second, we can work together to develop new markets for gamma sterilization. Candu reactors already supply the bulk of the world's cobalt 60 supply, and as you have heard, we can now work together to ensure that even more cobalt is required as medical product sterilization expands in the developing world.

Third, we can continue to build a bright future for nuclear medicine. In the case of nuclear diagnostics, the developing world is only now beginning to utilize this technology. There is also the potential for nuclear medicine to continue its growth

beyond imaging technology, as new radioisotope-based treatments are developed for a number of diseases, including heart disease.

Fourth, by putting our collective muscle into securing the necessary regulatory approvals here in Canada, we can ensure that food irradiation saves lives here at home. In fact, I believe it is our obligation to do so. Our collective experience and efforts can also be put towards thwarting the activists who would stand in the way of this life-saving process. I look forward to the opportunity to participate in these efforts with you.

Advances in nuclear power over the last 50 years have been tremendous. I, again, wish to commend each and every one of you for the contributions you have made to our collective success as an industry.

We have a story to tell. Is it about radioisotopes? Yes, but what it is really about is the success of Canadian nuclear science and the can-do attitude of pioneers like Roy Errington and of each of you here today.

I am confident that our 50-year partnership, which has brought us so much success, can be infused with new life and new goals. Together, we can make the next 50 years a future filled with even greater success stories. Thank you.